BR9709086A - Inibidores de metaloproteinase de matriz composição tendo atividade inibitoria de metaloprotease de matriz processos para inibir atividade de metaloprotease de matriz em um mamífero e para tratar um mamífero - Google Patents

Inibidores de metaloproteinase de matriz composição tendo atividade inibitoria de metaloprotease de matriz processos para inibir atividade de metaloprotease de matriz em um mamífero e para tratar um mamífero

Info

Publication number: BR9709086A
Authority: BR; Brazil
Prior art keywords: mammal; processes; matrix; matrix metalloprotease; treat
Prior art date: 1996-05-15

Application number

BR9709086A

Other languages

English (en)

Inventor

Michael C Van Zandt

David R Brittelli

Brian R Dixon

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-15

Filing date

1997-05-12

Publication date

1999-08-03

1997-05-12 Application filed by Bayer Ag filed Critical Bayer Ag

1999-08-03 Publication of BR9709086A publication Critical patent/BR9709086A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Oncology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Gynecology & Obstetrics (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Thiazole And Isothizaole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Peptides Or Proteins (AREA)

BR9709086A 1996-05-15 1997-05-12 Inibidores de metaloproteinase de matriz composição tendo atividade inibitoria de metaloprotease de matriz processos para inibir atividade de metaloprotease de matriz em um mamífero e para tratar um mamífero BR9709086A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US64849396A	1996-05-15	1996-05-15
PCT/US1997/007976 WO1997043239A1 (en)	1996-05-15	1997-05-12	Inhibition of matrix metalloproteases by 2-substituted-4-(4-substitutedphenyl)-4-oxobutyric acids

Publications (1)

Publication Number	Publication Date
BR9709086A true BR9709086A (pt)	1999-08-03

Family

ID=24601014

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9709086A BR9709086A (pt)	1996-05-15	1997-05-12	Inibidores de metaloproteinase de matriz composição tendo atividade inibitoria de metaloprotease de matriz processos para inibir atividade de metaloprotease de matriz em um mamífero e para tratar um mamífero

Country Status (24)

Country	Link
EP (1)	EP0923530B1 (pt)
JP (1)	JP3354942B2 (pt)
CN (1)	CN1100748C (pt)
AR (1)	AR007098A1 (pt)
AT (1)	ATE275123T1 (pt)
AU (1)	AU714207B2 (pt)
BR (1)	BR9709086A (pt)
CA (1)	CA2254731C (pt)
CO (1)	CO5011061A1 (pt)
DE (1)	DE69730508T2 (pt)
DK (1)	DK0923530T3 (pt)
ES (1)	ES2227696T3 (pt)
HR (1)	HRP970244B1 (pt)
ID (1)	ID17291A (pt)
MY (1)	MY132463A (pt)
PA (1)	PA8429701A1 (pt)
PE (1)	PE66898A1 (pt)
PT (1)	PT923530E (pt)
SV (1)	SV1997000036A (pt)
TN (1)	TNSN97083A1 (pt)
TW (1)	TW539672B (pt)
WO (1)	WO1997043239A1 (pt)
YU (1)	YU18597A (pt)
ZA (1)	ZA974030B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5925637A (en) *	1997-05-15	1999-07-20	Bayer Corporation	Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
US6288063B1 (en)	1998-05-27	2001-09-11	Bayer Corporation	Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
EP1031349A1 (en) *	1999-02-25	2000-08-30	Bayer Aktiengesellschaft	Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
GB9922710D0 (en) *	1999-09-24	1999-11-24	Bayer Ag	Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
PA8539401A1 (es) *	2001-02-14	2002-10-28	Warner Lambert Co	Quinazolinas como inhibidores de mmp-13
JP2004359546A (ja) *	2001-03-15	2004-12-24	Ono Pharmaceut Co Ltd	ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および／または治療剤
US20050119305A1 (en) *	2001-03-21	2005-06-02	Masao Naka	Il-6 production inhibitors
KR101405823B1 (ko) *	2007-12-24	2014-06-12	주식회사 케이티앤지생명과학	녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) *	2007-12-28	2009-07-02	주식회사 머젠스	신장질환의 치료 및 예방을 위한 약제 조성물
US9643922B2 (en)	2008-08-18	2017-05-09	Yale University	MIF modulators
US9540322B2 (en)	2008-08-18	2017-01-10	Yale University	MIF modulators
AU2009283195A1 (en) *	2008-08-18	2010-02-25	Yale University	MIF modulators
JP2017509665A (ja) *	2014-04-03	2017-04-06	バイエルファーマアクチエンゲゼルシャフト	気道疾患治療のための２，５−ジ置換されたシクロペンタンカルボン酸類
US20170022171A1 (en)	2014-04-03	2017-01-26	Bayer Pharma Aktiengesellschaft	2,5-disubstituted cyclopentanecarboxylic acids and their use
US20170119776A1 (en)	2014-04-03	2017-05-04	Bayer Pharma Aktiengesellschaft	Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
CN113979992B (zh) *	2021-11-19	2022-06-24	西安欧得光电材料有限公司	一种3-取代二苯并噻吩及其合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3827324B2 (ja) *	1994-01-22	2006-09-27	ブリテッシュバイオテックファーマシューティカルズリミテッド	金属タンパク質分解酵素阻害剤
ATE214368T1 (de)	1995-12-22	2002-03-15	Warner Lambert Co	Aromatische keto-säure und ihre derivate als inhibitoren der matrix metalloproteinase
CO5011071A1 (es)	1996-05-15	2001-02-28	Bayer Corp	Inhibicion de las metaloproteinasas de matriz por acidos 2-(w/aroilalquil)-4-biaril-4-oxobutiricos y composiciones farmaceuticas que los contienen

1997
- 1997-05-09 MY MYPI97002043A patent/MY132463A/en unknown
- 1997-05-09 HR HR970244A patent/HRP970244B1/xx not_active IP Right Cessation
- 1997-05-09 CO CO97025174A patent/CO5011061A1/es unknown
- 1997-05-09 TN TNTNSN97083A patent/TNSN97083A1/fr unknown
- 1997-05-09 ZA ZA9704030A patent/ZA974030B/xx unknown
- 1997-05-12 DE DE69730508T patent/DE69730508T2/de not_active Expired - Fee Related
- 1997-05-12 WO PCT/US1997/007976 patent/WO1997043239A1/en not_active Ceased
- 1997-05-12 PA PA19978429701A patent/PA8429701A1/es unknown
- 1997-05-12 CN CN97196454A patent/CN1100748C/zh not_active Expired - Fee Related
- 1997-05-12 AT AT97926455T patent/ATE275123T1/de not_active IP Right Cessation
- 1997-05-12 EP EP97926455A patent/EP0923530B1/en not_active Expired - Lifetime
- 1997-05-12 CA CA002254731A patent/CA2254731C/en not_active Expired - Fee Related
- 1997-05-12 PE PE1997000365A patent/PE66898A1/es not_active Application Discontinuation
- 1997-05-12 BR BR9709086A patent/BR9709086A/pt not_active Application Discontinuation
- 1997-05-12 YU YU18597A patent/YU18597A/sh unknown
- 1997-05-12 TW TW086106285A patent/TW539672B/zh not_active IP Right Cessation
- 1997-05-12 SV SV1997000036A patent/SV1997000036A/es not_active Application Discontinuation
- 1997-05-12 PT PT97926455T patent/PT923530E/pt unknown
- 1997-05-12 AU AU31220/97A patent/AU714207B2/en not_active Ceased
- 1997-05-12 ES ES97926455T patent/ES2227696T3/es not_active Expired - Lifetime
- 1997-05-12 AR ARP970101978A patent/AR007098A1/es unknown
- 1997-05-12 DK DK97926455T patent/DK0923530T3/da active
- 1997-05-12 JP JP54100397A patent/JP3354942B2/ja not_active Expired - Fee Related
- 1997-05-14 ID IDP971611A patent/ID17291A/id unknown

Also Published As

Publication number	Publication date
CA2254731A1 (en)	1997-11-20
DE69730508D1 (de)	2004-10-07
PE66898A1 (es)	1998-10-22
ES2227696T3 (es)	2005-04-01
HK1021897A1 (en)	2000-07-14
CN1100748C (zh)	2003-02-05
MY132463A (en)	2007-10-31
DK0923530T3 (da)	2005-01-03
DE69730508T2 (de)	2005-09-29
EP0923530A1 (en)	1999-06-23
JP3354942B2 (ja)	2002-12-09
JPH11510821A (ja)	1999-09-21
CA2254731C (en)	2004-07-20
HRP970244A2 (en)	1998-04-30
ID17291A (id)	1997-12-18
PT923530E (pt)	2004-12-31
AU714207B2 (en)	1999-12-23
HRP970244B1 (en)	2005-06-30
YU18597A (sh)	2001-12-26
ATE275123T1 (de)	2004-09-15
PA8429701A1 (es)	2000-05-24
TW539672B (en)	2003-07-01
WO1997043239A1 (en)	1997-11-20
ZA974030B (en)	1998-02-19
SV1997000036A (es)	1998-07-20
CN1225621A (zh)	1999-08-11
AU3122097A (en)	1997-12-05
TNSN97083A1 (fr)	2005-03-15
CO5011061A1 (es)	2001-02-28
AR007098A1 (es)	1999-10-13
EP0923530B1 (en)	2004-09-01

Publication	Publication Date	Title
BR9709086A (pt)	1999-08-03	Inibidores de metaloproteinase de matriz composição tendo atividade inibitoria de metaloprotease de matriz processos para inibir atividade de metaloprotease de matriz em um mamífero e para tratar um mamífero
ATE224364T1 (de)	2002-10-15	Beta-sulfonamido hydroxamsäure als matrix metalloproteinase und als tace inhibitoren
AR009356A1 (es)	2000-04-12	Compuesto de 1-4 heterociclico, inhibidor de la metaloproteasa y su uso para preparar una composicion farmaceutica y para prevenir o tratar una enfermedad asociada con la actividad de la metalo proteasa y la caquexia
BR9711988A (pt)	1999-08-24	Inibidores de metaloproteinase de matriz e seus empregos terap-uticos
DE69803592D1 (de)	2002-03-14	Kristallisationshemmung in transdermalen vorrichtungen
FI962905L (fi)	1996-07-19	Metalloproteinaasi-inhibiittoreita
AR002859A1 (es)	1998-04-29	Método y dispositivo para maquinar electroquimicamente
DE69815716D1 (de)	2003-07-24	Schlüssel zum verdrehen von sechseckigen muttern oder bolzen
FI960261A7 (fi)	1996-01-19	Biologinen aktiivisuuden tarkkailu jätevedessä
PT975638E (pt)	2002-12-31	Epothilons modificados nas cadeias laterais
DE69726624D1 (de)	2004-01-15	Thermostatventil zum Gebrauch in Notfalldusch- und Augenspülsystemen
NO20001323D0 (no)	2000-03-14	Dipeptid-apoptose inhibitorer og deres anvendelse
DE69807845D1 (de)	2002-10-17	Sulfamide-metalloprotease inhibitoren
PL337003A1 (en)	2000-07-31	Caprophen selectively acting on cox-2 in treating pains and inflammatory states among dogs
DE59705298D1 (de)	2001-12-13	Anlage zum automatischen zu- und abführen von rollen
FI972198A7 (fi)	1997-05-23	Metalloproteinaasi-inhibiittoreita
BR9709077A (pt)	1999-08-03	Compostos inibindo metaloproteinase de matriz composição tendo atividade inibitória de metaloprotease de matriz processos para inibir atividade de metaloprotease de matriz e para tratar um mamífero
ZA975631B (en)	1998-01-30	Matrix metalloproteinase inhibitors.
DE69824607D1 (de)	2004-07-22	VERBESSERUNGEN AN ODER IN BEZIEHUNG ZU ÜBERWACHUNGs- UND ANANLYSE-SYSTEMEN
BR9709084A (pt)	1999-08-03	Composto de inibição de metaloproteinase de matriz composição tendo atividade de inibição de metaloprotease de matriz e processos para inibir a atividade de metaloprotease de matriz em um mamífero e para tratar mamíferos
HUP9904165A3 (en)	2002-01-28	3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase and use thereof
EP0722321A4 (en)	1998-04-15	SULFOXIMIN AND SULFODIIMIN MATRIX METALLOPROTEINAS INHIBITORS
ZA979753B (en)	1998-05-22	Use of inhibitors of the activity of retinoic acid for treating sensitive skins and/or the acute damage induced by UV radiation.
NO996234L (no)	2000-03-10	Sprayformuleringer av antihyperalgesiske opiater og fremgangsmåte for behandling av topiske hyperalgesiske forhold og kløe med disse
TR199501429A2 (tr)	1996-06-21	Matriks metaloproteaz inhibitörlerinin yerine gecen 4-biarilpentanoik asitleri ve türevleri

Legal Events

Date	Code	Title	Description
2007-04-17	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2007-12-26	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements